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Positive Lysosomal Modulation As a Unique Strategy
to Treat Age-Related Protein Accumulation Diseases
Ben A. Bahr,1 Meagan L. Wisniewski,1 and David Butler2
Abstract
Lysosomes are involved in degrading and recycling cellular ingredients, and their disruption with age may
contribute to amyloidogenesis, paired helical filaments (PHFs), and a-synuclein and mutant huntingtin aggre-
gation. Lysosomal cathepsins are upregulated by accumulating proteins and more so by the modulator Z-
Phe-Ala-diazomethylketone (PADK). Such positive modulators of the lysosomal system have been studied in the
well-characterized hippocampal slice model of protein accumulation that exhibits the pathogenic cascade of tau
aggregation, tubulin breakdown, microtubule destabilization, transport failure, and synaptic decline. Active
cathepsins were upregulated by PADK; Rab proteins were modified as well, indicating enhanced trafficking,
whereas lysosome-associated membrane protein and proteasome markers were unchanged. Lysosomal modu-
lation reduced the pre-existing PHF deposits, restored tubulin structure and transport, and recovered synaptic
components. Further proof-of-principle studies used Alzheimer disease mouse models. It was recently reported
that systemic PADK administration caused dramatic increases in cathepsin B protein and activity levels, whereas
neprilysin, insulin-degrading enzyme, a-secretase, and b-secretase were unaffected by PADK. In the transgenic
models, PADK treatment resulted in clearance of intracellular amyloid beta (Ab) peptide and concomitant
reduction of extracellular deposits. Production of the less pathogenic Ab1–38 peptide corresponded with de-
creased levels of Ab1–42, supporting the lysosome’s antiamyloidogenic role through intracellular truncation.
Amelioration of synaptic and behavioral deficits also indicates a neuroprotective function of the lysosomal
system, identifying lysosomal modulation as an avenue for disease-modifying therapies. From the in vitro and
in vivo findings, unique lysosomal modulators represent a minimally invasive, pharmacologically controlled
strategy against protein accumulation disorders to enhance protein clearance, promote synaptic integrity, and
slow the progression of dementia.
Introduction
Lysosomes provide broad degradation pathways.Catabolic processes involve cooperation between autop-
hagic trafficking and enzyme delivery for efficient degrada-
tion and turnover of proteins and other material. Altered
protein-processing capability in lysosomes has been sug-
gested to affect brain function during normal aging as well as
in age-related diseases. Lysosomal instability is a distinct
feature of brain aging,1,2 resulting in gradual changes and
increased risk for protein accumulations and aggregated
protein stress responses. Such occurrences contribute to the
neurodegeneration of protein accumulation diseases (PADs)
and are related to the aberrant protein and glycoconjugate
aggregates of devastating lysosomal storage disorders
(LSDs). Disruption of key clearance mechanisms is believed
to underlie many neurodegenerative events of PADs and
LSDs, leading to abnormal brain development in LSDs, dy-
namic changes to synapses in both, and associated cognitive
deterioration.
Some cellular accumulations are shared by LSDs and
PADs,3,4 and evidence suggests that lysosomal disturbances
play a role in both. Lysosome dysfunction is associated with
the early-onset LSDs and also appears to play a role in later-
onset diseases including: (1) Alzheimer disease and related
tauopathies (frontotemporal dementia), (2) Lewy body dis-
orders and synucleinopathies such as Parkinson disease, (3)
Huntington disease and other polyglutamine expansion
disorders, and (4) prion encephalopathies (reviewed in ref.
5). Related to PADs, the aged brain exhibits the risk factor of
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compromised cellular pathways that remove damaged and
misfolded proteins. Recently, clearance rates for amyloid
beta (Ab) peptides were found to be slower in Alzheimer
disease as compared to the rates in cognitively normal in-
dividuals,6 implicating an imbalance in Ab production ver-
sus clearance as a plausible mechanism for Ab dysregulation.
Perhaps related, lysosomes have a propensity for age-related
free radical formation through aberrant products from in-
complete catabolism, and their membranes can be targeted
by oxidative damage. This leads to disruption of the im-
portant balance between protein synthesis and breakdown.
Resultant overloading of lysosomal capacity and decay of
efficient catabolic functions likely contribute to the aging risk
factor for neurodegenerative PADs and many aspects of LSD
pathology.
Experimentally induced lysosomal disturbances in a brain
slice model cause distinct pathogenic changes, including
protein deposition, reduced staining of synapses, dystrophic
neurites, cytoskeletal breakdown, and eventual cell death. In
fact, a striking resemblance is apparent between the hippo-
campal slice model of protein accumulation and the Alz-
heimer disease brain regarding the loss of synaptic integrity
as well as axonopathy and associated transport failure.7–9
One of the earliest events linked to lysosomal disturbances is
the reduction in pre- and postsynaptic markers. Synapses
also experience dynamic changes in Alzheimer disease, with
synaptic loss well established as the best neurobiological
correlate of the cognitive deficits.10 Understanding the
functional synaptic dynamics as well as synaptopathogenic
cascades elicited by protein accumulation will be critical in
the fight to offset progressive cognitive decline. Promoting
the clearance of pathogenic accumulations is the key com-
monality regarding therapeutic development for the wide
range of PADs and LSDs. Here, we will summarize the
findings showing that the lysosomal system can be func-
tionally modulated by a variety of agents, and, with selective
compounds, that positive lysosomal modulation in in vitro
and in vivo proof-of-principle studies provides neuroprotec-
tion against protein accumulation pathology. Positive mod-
ulators of clearance mechanisms represent a strategy against
protein accumulation disorders, taking into consideration, of
course, the pathogenic stage at which treatment is to be
administered.
Synaptic Vulnerability and Lysosomal Compromise
Destabilization and loss of central synapses and cerebral
activity occur during aging and in age-related dementias,10–13
indicating that synaptic pathology is a key contributor to
cognitive decline. Associated with related protein accumu-
lation events, integrity of synapses, axons, and neuronal
communication exhibit distinct vulnerability during periods
of lysosomal dysfunction.5,14 Lysosomal disruption has been
implicated in the development of amyloidogenic oligomers
and paired helical filament tau (PHF-tau) that forms neuro-
fibrillary tangles. In Alzheimer brains, transgenic mouse
models, and the hippocampal slice model, amyloidogenic
species have a tendency to accumulate intracellularly at
synaptic connections, and this is associated with signs of
synaptic pathology.15,16 In the models and in Alzheimer
tissue, synaptic markers and their expression are reduced in
neurons containing tau species that aggregate as PHFs and
neurofibrillary tangles.7,17 Lysosomal dysfunction in in vitro
and in vivo experimental models recapitulates many patho-
logical features of age-related PADs, including the link be-
tween protein deposition and synaptic deterioration. The
induced lysosomal dysfunction produced intracellular olig-
omeric species and protein aggregation, causing a charac-
teristic cascade of microtubule destabilization, transport
failure, and synaptic compromise. Such a pathogenic cascade
is likely responsible for loss of synapses and associated
cognitive decline. Both pre- and postsynaptic markers are
reduced at the protein and message levels, and synapse
function is compromised as evidenced by the gradual de-
crease in evoked excitatory responses. Note that in the slice
model, the degree of synaptic decline correlates with lyso-
somal dysfunction-induced protein accumulation. Increased
understanding of the cellular changes that lead to synaptic
and cognitive dysfunction will help develop new protection
strategies.
Positive Lysosomal Modulation
Lysosomes and autophagolysosomes are thought to be
activated for the clearance of toxic accumulation events.
Potential compensatory changes to the lysosomal system, as
indicated by the upregulation of catabolic enzymes, are ev-
ident during normal aging and are a characteristic feature
of the Alzheimer brain.8,17–19 Enhanced levels of lysosomal
enzymes are particularly apparent in familial Alzheimer
disease and in related transgenic mouse models.20,21 Evi-
dence of lysosomal changes has also been found among
LSDs. Metabolically compromised animals comparable to
Niemann–Pick disease and Gaucher disease exhibit elevated
activities of several lysosomal hydrolases during the cellular
accumulation of lipids. In addition, mannose 6-phosphorylated
glycoproteins and hydrolases are elevated in the brain in
juvenile neuronal ceroid lipofuscinoses.22 The increased ly-
sosomal enzyme activities likely indicate cellular responses
aimed to compensate for accumulating material. The exam-
ples of endogenous lysosomal enhancement illustrate sur-
vival tactics of the obstinate brain.
Protein oligomerization and aggregation may trigger a
lysosomal response in an attempt to prevent the formation of
intracellular deposits and, in doing so, slow associated neu-
rodegeneration. This is supported by the fact that message,
protein, and activity levels of lysosomal cathepsins are in-
creased in brain tissue and a neuronal cell line when exposed
to the Alzheimer disease Ab1–42 peptide.
20,23 Ab can target
lysosomes and produce detrimental effects regarding their
functionality,24 and a recent study has reported higher
plasma cathepsin B levels in persons with Alzheimer disease
compared to healthy individuals.25 The lysosomal response
occurred in correspondence with protein accumulation dur-
ing Ab exposure as well as during episodes of induced ly-
sosomal dysfunction.23,26 Lysosomal stress in cultured brain
tissue not only caused gradual amyloidogenic changes and
tau accumulation, but it also markedly upregulated a broad
spectrum of lysosomal hydrolases. Thus, it is clear that
protein accumulation events can elicit positive modulation of
lysosomal enzyme expression, although the modulatory re-
sponses only have a small or negligible influence on the ly-
sosome’s ability to process the accumulating material. It
could also be the case that, because lysosomal activity can
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contribute to oxidative damage under certain circum-
stances,27 the compensatory hydrolase increases may aug-
ment lysosomal stress and actually reduce processing
capability in particular cellular states.
Using chloroquine, a weak base that attenuates protein
processing by disrupting the lysosomal pH gradient through
proton trapping, the hippocampal slice model of protein
accumulation established that the resultant lysosomal re-
sponse involves a range of hydrolases (Table 1). The broad
lysosomal activation involves cysteine proteases cathepsins B
and L, the aspartic acid protease cathepsin D, b-glucuronidase,
and likely other components of the lysosome. An indication
that the lysosomal response is part of compensatory signal-
ing comes from the fact that b-glucuronidase is among the
endosomal–lysosomal components highly expressed in Ab-
resistant neurons.28 Cathepsin B has also been implicated in
the cleavage of Ab1–42 into less amyloidogenic species.
20,29 A
wide variety of agents are listed in Table 1 that have been
found to elicit positive lysosomal modulation. Chloroquine
and bafilomycin A1, the latter being an adenosine tripho-
sphatase (ATPase) blocker that also disrupts lysosomal pH,
both cause lysosomal stress resulting in hydrolase responses.
The lysosomal stress produced by the two agents is associ-
ated with synaptic marker decline,30 indicating an overall
compromise of protein clearance and cellular homeostasis.
Protein accumulation stress produced by Ab peptides also
upregulates the message, protein, and activity levels of ca-
thepsin B and cathepsin D (see Table 1). Uniquely elicited
lysosomal stress may be involved in the cellular response to
Ab1–42, a peptide that is taken up by neurons and stably
sequestered in lysosomes,15,24,31 perhaps allowing a modest
route of Ab detoxification. As mentioned, cathepsin B ap-
pears to be among a small group of Ab-degrading en-
zymes, including neprilysin, insulin-degrading enzyme, and
endothelin-converting enzyme, which may be responsible for
Ab homeostasis in the brain.
Among the diverse agents in Table 1, several inhibitors of
lysosomal hydrolases are listed that elicit a paradoxical effect
of positive lysosomal modulation, upregulating the same
hydrolases targeted by the inhibitors as well as unrelated
hydrolases. For instance, leupeptin, the broad-acting inhibi-
tor of serine, cysteine, and threonine proteases, used at up to
200 mg/kg, caused the expected inhibition of cathepsins B
and L in different tissues. However, after clearance of the
administered leupeptin, not only did the cathepsin activities
recover to control levels they increased more than two-
fold.32,33 E-64c, a potent and irreversible cysteine protease
inhibitor also known as Ep-475, not only increased the ma-
ture forms of cathepsins B, H, and L by two- to four-fold, but
also caused two- to three-fold increases in b-glucuronidase,
b-galactosidase, b-hexosamidase, and arylsulfatase activity.34
Also listed are two examples of glycohydrolase inhibitors
that act as pharmacological chaperones for potential LSD
treatments: (1) the b-hexosaminidase inhibitor M-31850 that
increased b-hexosaminidase A activity in fibroblasts from
adult-form Tay–Sachs disease and infantile Sandhoff
disease,35 and (2) isofagomine, which raised the level of b-
glucocerebrosidase in Gaucher disease fibroblasts, as did two
noncarbohydrate-based inhibitors of b-glucocerebrosidase.36
The b-glucocerebrosidase inhibitors enhanced lysosomal
transport of the enzyme, resulting in increased functional b-
glucocerebrosidase in lysosomes of the treated fibroblasts.
M-31850 and two related b-hexosaminidase inhibitors selec-
tively raised the enzyme activity in the lysosomal fraction of
treated cells, likely by stabilizing the proper folding of the
mutant b-hexosaminidase, thereby promoting endoplasmic
reticulum export and subsequent trafficking to the en-
dosomal–lysosomal compartment. Although effective as
pharmacological chaperones when administered at low
Table 1. Positive Lysosomal Modulation Initiated
by Protease Inhibitors and Other Factors
Agent Modulation effect References
Protease inhibitors:
DAME Increased proCD (brain slice) 23
E-64 Increased intCL, transient
increase in proCL
(fibroblasts)
33
E-64 Increased proCD (brain slice) 26
E-64c
(20 mg/kg)
Increased matCB, matCH,
matCL (liver)
34
E-64c
(20 mg/kg)
Increased A-Sul, b-gal,
b-gluc, b-hex activity
(liver)
34
GFGas Increased proCD (brain slice) 23
Leupeptin
(200 mg/kg)
Delayed increase in CB
activity (liver, heart,
muscle)
32
Leupeptin Increased proCD (brain slice) 26
Pepstatin A Increased proCD (brain slice) 26
PADK Increased intCL (long-term),
increased proCL
(fibroblasts)
33
PADK Increased inta-man, intb-gluc
(Dictyostelium discoideum)
52
PADK Increased matCB, CD, CS,
elastase (brain slice)
8, 23, 38
PADK
(18–20 mg/kg)
Increased matCB, intCD, CB
activity (brain)
29
Glycohydrolase inhibitors (pharmacological chaperones):
Hex inhibitor
M-31850
Increased lysosomal Hex A
activity (ATSD fibroblasts)
35
Isofagomine Increased lysosomal GCase
(GD fibroblasts)
36
Peptides and proteins:
Ab1–42 Increased matCD (brain slice) 8, 23
Ab1–42 Increased CB mRNA, activity
(neurons)
20
Ab1–40
(aggregated)
Increased CB activity
(neurons)
20
Huntingtin Increased intCD, CL (striatal
x57 cells, PC12 cells)
41
Ionotropic agents:
Chloroquine Increased matCB, CD, CL,
b-gluc (brain slice)
8, 23, 26
Bafilomycin A1 Increased matCD (neurons) 50
Agents reported to increase the proform (pro), intermediate (int),
and mature forms (mat) of enzymes or their activity levels are listed,
with organ location or model utilized provided. Dosages of in vivo
studies are shown.
a-man, a-mannosidase; A-Sul, arylsulfatase; b-gal, b-galactosidase;
b-glu, b-glucosidase; b-gluc, b-glucuronidase; b-hex, b-hexosamidase;
CB, cathepsin B; CD, cathepsin D; CL, cathepsin L; CS, cathepsin S;
DAME, diazoacetyl-dl-2-aminohexanoic acid methyl ester; GCase, b-
glucocerebrosidase; GFGas, glycyl-phenylalanyl-glycine-aldehyde
semicarbazone; Hex, b-hexosaminidase A; PADK, Z-Phe-Ala-diazo-
methylketone.
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levels, high concentrations of the compounds produced
nonselective inhibitory effects, leading to cellular toxicity.
Adverse cellular changes also occur with high levels of
the cathepsin B and L inhibitor N-Cbz-l-phenylalanyl-l-
alanyl-diazomethylketone (PADK; also known as ZPADK,
ZPAD, and Z-Phe-Ala-CHN2) in brain tissue.
30,37 However,
low PADK concentrations dramatically increase cathepsin
isoforms and other hydrolases without producing any indi-
cations of cellular or synaptic pathology after extended
treatment.8,21,23,29,30,38 Different active cathepsin forms were
upregulated with evidence of enhanced trafficking of the
hydrolases to lysosomes, whereas the low concentration
PADK had no influences related to axonopathy, axonal ini-
tial segment atrophy, or somatofugal transport failure.
Broad lysosomal stress through inhibition of multiple
hydrolases, as with the actions of chloroquine, bafilomycin
A1, and leupeptin, may be adept at triggering a feedback
response, perhaps related to the feedback mechanism re-
ferred to when continuous proteasome inhibitor treatment
was found to increase proteasome components and inhibitor
resistance.39 On the other hand, compared to the broad ly-
sosomal stressors, a much higher degree of positive lyso-
somal modulation is produced by PADK, the selective
inhibitor of two thiol proteases, as well as by the specific ca-
thepsin D inhibitor diazoacetyl-dl-2-aminohexanoic acid
methyl ester and the cathepsin B inhibitor glycyl-
phenylalanyl-glycine-aldehyde semicarbazone.23 Distinct
mechanisms may be involved because chloroquine and
PADK are dissimilar in their ability to produce an additive
lysosomal response with Ab1–42.
8 PADK does not appear to
influence proteasome markers, and its lack of influence on
lysosomal marker lysosomal-associated membrane protein 1
(LAMP1) levels or the number of cathepsin-positive organ-
elles would appear to rule out any broad effect on lysosomal
biogenesis.23,29 Table 1 shows that lower PADK concentra-
tions increase the expression of cathepsins B, D, L, and S and
enhance active intermediate forms of a variety of hydrolases.
As mentioned, cathepsin B is a suspected Ab-degrading
enzyme that is increased in Alzheimer disease and related
transgenic mice.19,20 Increases in cellular levels of hydrolase
intermediates by modulatory concentrations of PADK may
signify enhanced lysosomal transport of the enzymes and
more efficient maturation, thereby improving clearance of
material delivered to lysosomes.
Lysosomal Enhancement to Promote
Cellular Recovery
Knowing the link between lysosomal dysfunction and
selective pathogenesis, one logical step toward therapeutic
intervention is the enhancement of enzymatic activity in ly-
sosomes. Age-related PADs and developmental LSDs may
be slowed or reversed by the positive modulation of the ly-
sosomal system. Many studies suggest that lysosomal acti-
vation occurs with age and in diseased brains,8,17,18 but not
to the necessary extent that would prevent the gradual loss
of neuronal integrity and brain function. Enhancement of
lysosomal function has been proposed as a plausible strategy
to reduce protein accumulation events in age-related disor-
ders, including those events in Alzeimer disease, Parkinson
disease, and Huntington disease.8,20,23,29,40–46 Several of the
studies indicate that induction of protein degradation pro-
cesses is an attempt to clear amyloid peptides and tau spe-
cies, as well as a-synuclein and mutant huntingtin. Another
potential therapeutic strategy that may involve the en-
dosomal–lysosomal system is the disaggregation of extra-
cellular Ab peptide, with the idea that the disaggregation
would promote uptake of monomers and small oligomers
into neurons and microglia where they are trafficked to ly-
sosomes for degradation by cysteine proteases, including
cathepsin B.15,29,47 Note that besides the disaggregation of
intra- and extracellular Ab to facilitate clearance in this
manner, extracellular proaggregation of soluble Ab oligo-
mers has been proposed as protective,48 whereby the for-
mation of large nontoxic complexes reduces the smaller
oligomeric species that are responsible for synaptic pathol-
ogy and cognitive deterioration.
Of the list of lysosomal modulatory agents in Table 1, only
PADK, diazoacetyl-dl-2-aminohexanoic acid methyl ester,
glycyl-phenylalanyl-glycine-aldehyde semicarbazone, and
bafilomycin A1 have been reported to elicit protection
against protein accumulation pathology under appropriate
low-dose conditions, and of these all but bafilomycin A1 are
selective cathepsin inhibitors. Low-dose bafilomycin A1
(0.1—1 nM) was found to be cytoprotective against chloro-
quine-induced accumulation pathology in human neuroblas-
toma cells, the protection being in part through bafilomycin
A1’s ability to maintain the autophagy–lysosomal path-
way.49 Synaptic protection against chloroquine-mediated
pathology in hippocampus was also produced by 1 lM of the
specific cathepsin D inhibitor diazoacetyl-dl-2-aminohexanoic
acid methyl ester, and similar results were found with the
cathepsin B inhibitor glycyl-phenylalanyl-glycine-aldehyde
semicarbazone.23 PADK, a mild inhibitor of cathepsins B and
L, is probably the most studied agent regarding lysosomal
modulation and the protective clearance of toxic proteins in
models of protein accumulation pathology.
Low-level PADK produces apparent enhancement of
hydrolase trafficking and maturation, thereby improving
the clearance capacity of lysosomes (Fig. 1A). The brains of
PADK-treated animals exhibited increased levels of ca-
thepsin proenzyme forms.8,29 In addition, the mature forms
of cathepsin B increased much more as compared to the
PADK effect on the proform of the enzyme. Thus, besides
enhanced expression, these findings implicate trafficking
and maturation as major components of the PADK effect
because inactive procathepsin forms are processed to the
active forms in late endosomes and lysosomes. PADK-me-
diated changes in trafficking/maturation were also sup-
ported by effects on the Rab5a marker of early endosomes
in brain slice cultures.29 Positive modulation of traffick-
ing and maturation of enzymes would increase the lyso-
somal content of active hydrolases and enhance their
clearance capacity for protection against protein accumu-
lation pathology.
First tests of the idea of protective lysosomal modulation
used the hippocampal slice model of protein accumulation
pathology. Slice cultures treated with the lysosomal inhibitor
chloroquine exhibited increased levels of tau isoforms and
other aggregation-prone proteins found to accumulate in the
aged brain and age-related diseases.7,26,30,50 Evident in the
model was a pathogenic cascade consisting of PHF-tau accu-
mulation in neurons, tubulin breakdown, microtubule desta-
bilization, transport failure, and gradual synaptic decline that
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included the loss of pre- and postsynaptic proteins. Gradual
loss of transport occurred as protein deposits and microtubule
deterioration became evident. A microtubule-stabilizing agent
was used to show that, indeed, disruption of microtubule
integrity accounted for the chloroquine-induced synaptic de-
cline.51 Upon removal of the lysosomal disruptor, the protein
accumulation events continued to persist, especially in pyra-
midal neurons. In contrast, when chloroquine was replaced by
the positive lysosomal modulator PADK, the three- to eight-
fold enhancement of lysosomal enzymes was associated with
the clearance of protein oligomers and aggregates.8,23 The
PADK treatment generated pronounced increases in cathepsin
isoforms as compared to the modestly elevated levels found in
response to the chloroquine-mediated lysosomal stress, the
result being enhanced lysosomal function with the capacity to
clear pre-existing protein deposits.
In addition to clearance of PHF-tau and amyloidogenic
fragments, lysosomal enhancement also led to indications
of microtubule stabilization, further establishing a link be-
tween protein accumulation and the loss of microtubule in-
tegrity.7,23 In the slice model, chloroquine-induced protein
accumulation was found to be associated with reduced mi-
crotubule integrity by assessing tubulin acetylation, a specific
posttranslational modification that indicates stable microtu-
bules. Disruption of microtubules and transport capability is
thought to be a key contributor to Alzheimer disease. Re-
duced levels of acetylated tubulin as well as increased tu-
bulin fragmentation occurred in close association in the
protein accumulation model. These changes also signifi-
cantly correlated with transport failure and the reduction in
excitatory postsynaptic potential (EPSP) size when measur-
ing synaptic responses in the CA1 region.7,30 The cellular
content of acetylated tubulin was gradually restored by
PADK-mediated lysosomal enhancement to levels similar to
those expressed by control slices.23 Importantly, the positive
influence on microtubule integrity by lysosomal enhance-
ment was further indicated by the restoration of microtu-
bule-based transport through distal dendritic branches, spine
structures, and long axons.
Positive lysosomal modulation elicited protection against
the pre-existing protein accumulation events in the slice
model, thus indicating that the protein deposition–microtubule
destabilization–transport failure–synaptic decay cascade is
able to be reversed. In addition to the recovery of microtu-
bule stability markers, transport function, and tubulin-
binding proteins in hippocampal slices treated with low-dose
PADK, synaptic proteins also exhibited concomitant recov-
ery as well as improved maintenance. The lysosomal mod-
ulation elicited many indications of pre- and postsynaptic
maintenance,8,23,38 including protected levels of synaptic
vesicle proteins, different a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor subunits (GluR1,
GluR2, GluR3), N-methyl d-aspartate (NMDA)-type gluta-
mate receptors, and other neurotransmitter receptors. In
addition, improved levels were found for stargazin, a
member of the transmembrane AMPA receptor regulatory
proteins (TARP) family of transmembrane AMPA receptor-
associated proteins, and other proteins involved in the traf-
ficking and clustering of transmitter receptors in central
neurons.38 Together, these findings indicate that, at early-
stage protein accumulation pathology before overt neuronal
degeneration, pharmacologically-controlled modulation of
FIG. 1. (A) Lysosomal modulation increases the cathepsin B
content of lysosomes and reduces intracellular amyloid beta
1–42 (Ab1–42) in APPswe/PS1dE9 hippocampus. The lysosomal
modulator Z-Phe-Ala-diazomethylketone (PADK) has been
shown to increase expression of procathepsin B (proCB), as well
as produce molecular changes consistent with enhanced ca-
thepsin maturation and trafficking.8,23,29 The latter steps may
involve processing/trafficking of active intermediate (intCB)
and mature forms (matCB) of cathepsin B from early endosomes
and late endosomes, and subsequently to lysosomes to promote
protein degradation. (B) To confirm localization, hippocampal
tissue from PADK-treated mice (intraperitoneally, 20 mg/kg per
day · 9 days) exhibiting increased mature cathepsin B levels was
stained with anti-cathepsin B (red) and anti- lysosomal-associ-
ated membrane protein 1 (LAMP1) (green). The merged image
shows that the PADK-modulated hydrolase highly co-localizes
with LAMP1-positive lysosomes in pyramidal neurons. (C) The
increase in organellar cathepsin B (red) in PADK-treated
APPswe/PS1dE9 transgenic mice (tg) was associated with a
decrease in intracellular Ab1–42 in CA1 pyramidal neurons. Ar-
rows denote co-localization in organelles, the image capturing
intact Ab1–42 before being digested by cathepsin B. View-field
widths, &12 lm. wt, Vehicle-treated wild-type mice.
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the lysosomal system provides: (1) Enhanced clearance of
protein deposits, (2) restoration of microtubule integrity, (3)
re-establishment of vital transport mechanisms, and (4)
synaptic and functional recovery.
Following the in vitro proof-of-principle studies, recent
work tested the effect of positive lysosomal modulation in
transgenic mouse models of Alzheimer disease.29 As in the
hippocampal slice model in which the novel approach re-
duced PHF-tau species, comparable effects on Ab clearance
and synaptic protection were produced by a lysosomal
modulator in transgenic mice. The modulator PADK, when
administered intraperitoneally into mice daily for 1–2 weeks,
enhanced the cathepsin B levels in pyramidal neurons in the
brain, with no effect on neuronal morphology or cell density.
The PADK treatment influenced the lysosomal content of
cathepsin B as determined in brain tissue double-stained for
cathepsin B and LAMP1, the merged immunofluorescence
image showing that the modulated cathepsin B co-localized
with LAMP1-positive organelles in pyramidal neurons (Fig.
1B). While intracellular cathepsin B levels increased mark-
edly, the number of cathepsin B-positive organelles per
neuron and the level of LAMP1 staining were unchanged.
Thus, as confirmed by measuring cathepsin B activity in
isolated lysosomes,29 lysosomal modulator treatment en-
hanced the content of active cathepsin B in lysosomes.
As a test of whether lysosomal proteolytic activity can be
enhanced to reduce Ab accumulation, the PADK injections in
APPSwInd and APPswe/PS1dE9 transgenic mice caused 3- to
10-fold increases in cathepsin B activity, whereas neprilysin
and insulin-degrading enzyme were unchanged.29 The up-
regulated levels of cathepsin B corresponded with reduced
levels of Ab1–42. Brain sections from the different APPswe/
PS1dE9 treatment groups were double-stained for Ab1–42
(green) and cathepsin B (red) to distinctly show the link
between the positive modulation of cathepsin B in neurons
and the clearance of intracellular Ab1–42 (Fig. 1C). The im-
munofluorescence images revealed punctate Ab1–42–positive
material within CA1 pyramidal neurons, and the intracellu-
lar accumulation was reduced by PADK in correspondence
with enhanced labeling intensity of cathepsin B-positive
organelles. The sparse number of organelles exhibiting co-
localization of cathepsin B and intact Ab1–42 (arrows) pro-
vides further evidence of the efficient degradation of Ab1–42
peptide within positively modulated lysosomes.
These experiments, using two different transgenic mouse
models, suggest that positive modulation of lysosomal en-
zymes starting at early or latter stages of Alzheimer disease
can promote protective clearance of toxic material.29 The
enhanced clearance of intracellular Ab also led to the re-
duction of extracellular deposits, thus suggesting new ideas
regarding Ab metabolism as well as equilibrium processes
that contribute to the dynamics of extracellular protein de-
position. Using an alternative approach, lentiviral delivery of
cathepsin B was shown to significantly reduce Ab accumu-
lation in a transgenic mouse model, whereas the genetic
inactivation of the cathepsin increased the abundance of
Ab1–42.
20 Together, the findings further implicate cathepsin B
as an Ab-degrading enzyme, both studies indicating that
cathepsin B plays an anti-amyloidogenic role by degrading
Ab1–42 into less pathogenic peptide species.
The evidence of intracellular Ab clearance and concomitant
reduction of extracellular deposits by the lysosomal modulator
PADK were found to protect against further aspects of protein
accumulation pathology.29 The findings suggest that positive
lysosomal modulation reduces Ab1–42 through intracellular
truncation that also influences extracellular deposition, with
one or both effects explaining the elimination of behavioral and
synaptic protein deficits in two transgenic mouse models.
Figure 2 shows PADK-mediated reduction of Hematoxylin &
Eosin–stained deposits in the hippocampal neuropil of
APPswe/PS1dE9 transgenic mice. The protein clearance was
associated with the preservation of neuronal integrity, as in-
dicated by the recovered distribution of calbindin labeling.
Learning deficits have been previously shown to correlate
FIG. 2. The lysosomal modulator Z-Phe-Ala-diazomethylketone (PADK) reduces protein deposits and preserves neuronal
integrity in hippocampus of APPswe/PS1dE9 transgenic mice. APPswe/PS1dE9 mice (tg) of 20–22 months were treated with
PADK (intraperitoneally, 20 mg/kg per day) or vehicle for 11 days, and nontransgenic control mice (wt) received vehicle
injections. Fixed sections were Hematoxylin & Eosin–stained (top) and assessed for calbindin immunolabeling (bottom).
Typical extracellular deposits of the APPswe/PS1dE9 mice (arrows denote two of them) were dramatically reduced in
number by lysosomal modulation in the stratum radiatum and other brain areas. Recovery of calbindin-positive structures
and cellular expression was also produced, especially evident in the CA1 dendritic fields and the molecular layer of the
dentate gyrus. View-field width, approximately 1.8 mm. H & E, Hematoxylin & Eosin; DG, dentate gyrus; ml, molecular
layer; so, stratum oriens; sr, stratum radiatum. (Color image is available online at www.liebertpub.com/rej).
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strongly with the depletion of the calcium-binding protein in
hippocampus, and mice that had cathepsin B genetically in-
activated had lower hippocampal calbindin staining, consis-
tent with their increased Ab1–42 levels.
20 In addition to the
recovery of calbindin-positive dendrites and cellular expres-
sion, PADK-treated APPSwInd and APPswe/PS1dE9 mice ex-
hibited similar indications of pre- and postsynaptic
protection.29 The lysosomal modulation preserved measures of
specific markers of synaptic components, and, in fact, im-
proved levels of a neurotransmitter receptor subunit signifi-
cantly correlated with the degree of cathepsin B enhancement
in the brain. The PADK-mediated clearance and synaptic
protection translated to behavioral protection as the treated
mice exhibited reduced deficits in motor memory, exploratory
inhibition, and episodic memory tasks.
Positive modulation of cathepsin expression and trafficking
of the hydrolases may enhance the cooperation between au-
tophagosomes and lysosomes to promote catabolic processes
and control toxic material that builds up as the brain ages.
Perhaps in PADs, as well as in LSDs, endogenous compensa-
tory signaling occurs in response to the toxic buildup, although
at insufficient levels to prevent accumulation pathology and
associated neuronal compromise. Such endogenous responses
may delay overt neurodegeneration and account for the
gradual disease progression often exhibited by several types of
protein accumulation pathology. Lysosomes are the primary
site for removal of misfolded and accumulating proteins to
maintain cellular homeostasis, and enhancing lysosomal
function above that produced by the endogenous modulatory
response can protect the brain against a distinct pathogenic
cascade. Reducing accumulation events in neurons and other
cells is essential for slowing the progression of PADs and LSDs.
Small-molecule lysosomal modulators like PADK support the
concept of pharmacologically controlled lysosomal enhance-
ment to remove toxic deposits and offset cognitive decline.
Members of the new class of compounds are being tested in
aged animals and in models of frontotemporal dementia and
LSDs. Development of efficacious lysosomal modulators will
further the efforts to provide a therapeutic avenue that en-
hances protein clearance, promotes synaptic integrity, and
slows the progression of proteinopathies.
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